About US
Contact us
-
J&J's BCMA bispecific Tecvayli wins FDA approval in multiple myeloma—but as a late-line therapyAfter European regulators jumped on a global-first approval for Johnson & Johnson’s BCMA-targeted bispecific drug Tecvayli, the U.S. FDA has doled out its own blessing for the novel therapy. But2022/10/24
-
GSK shuffles execs and streamlines businesses as vaccines chief Connor heads for the exitNow unburdened by its consumer health division, GSK is streamlining its drug and vaccines businesses and shuffling executives in turn. On the quest to simplify its operations in a post-Ha2022/10/24
-
FDA approves single-vial version of GSK's Menveo vaccine, ending need for reconstitutionGSK haswonFDA approval for a single-vial formulation of its meningococcal disease vaccine Menveo, thereby ending the need for reconstitution that has existed since the product came to market in 2010.2022/10/19
-
Roche recalls new eye therapy Susvimo on leakage fears, aims for market return 'within a year or so'Just as doctors were starting to cozy up to Roche and Genentech’s new eye drug delivery therapy, the companies are pulling the product from U.S. shelves. Roche has launched a voluntary re2022/10/19
-
Love Pharma moves to buy transdermal opioid-use disorder playerLove Pharma hasstrucka deal to acquire transdermal drug delivery technology, signing a letter of intent to buy Naltrexone Therapeutics for intellectual property covering the administration of a treat2022/10/17
-
Surge raises $26M to take anti-cancer extended-release hydrogel into the clinicSurge Therapeutics hasraisedmoney to take its extended-release biodegradable hydrogel into the clinic, reeling in $26 million to test its belief that implanting the scaffolds after surgery will impro2022/10/17
-
Novartis' Sandoz sells Chinese finished drugs plant to CDMO Jiuzhou for $15.1MEven as Novartis works to separate Sandoz, the Swiss parent hasn’t stopped making deals for the outgoing generics subsidiary. Chinese CDMO Jiuzhou Pharmaceutical said it plans to buy a Sa2022/10/14
-
Asymchem Labs in early planning for $697M manufacturing facility in ChinaAsymchem Labs, a Chinese CDMO, is in the early phases ofplanning(PDF) a 4 billion Chinese yuan to 5 billion Chinese yuan ($557 million to $697 million) manufacturing campus on the outskirts of Shangh2022/10/14
-
WuXi's expansion tear rolls on with new high-potency oral production facilityWuXi STA, a subsidiary of WuXi AppTec,continued its expansion march with theopeningof the Chinese CDMO’s first high-potency oral drug production plant located on the WuXi City campus near Shanghai.2022/10/12
-
Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug EzharmiaWhile Daiichi Sankyo has been focusing on a stable of antibody-drug conjugates, the Japanese company has won a global first in an area that Pfizer is also targeting. Daiichi Sankyo has wo2022/10/12